Dendritic cell immunotherapy: clinical outcomes

The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alt...

Full description

Bibliographic Details
Main Authors: Apostolopoulos, Vasso, Pietersz, Geoffrey A, Tsibanis, Anastasios, Tsikkinis, Annivas, Stojanovska, Lily, McKenzie, Ian FC, Vassilaros, Stamatis
Format: Online
Language:English
Published: Nature Publishing Group 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232065/